Sign In
Last checked at 
1 Apr 2026 07:00
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company" or the "Group")
Suspension of Trading
1 April 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that trading in the Company's ordinary shares will be suspended with effect from 7.30am today as a consequence of the Company not announcing the interim results for the 6 months ended 31 December 2025 ("Interim Results") by 31 March 2026, as required by the AIM Rules for Companies.
The previously announced Board investigation and the independent, forensic review being undertaken by FRP Advisory continues to progress and the Board is hopeful that these will be concluded later this month. Trading in the Company's ordinary shares is anticipated to resume upon the publication of the Interim Results.
The Board will update shareholders on the result of the forensic review and Board investigation as soon as possible.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
-Ends-
For more information please contact:
SkinBioTherapeutics plc Martin Hunt, Executive ChairmanRachel Parsonage, Interim CEOEmily Bertram, CFO | ir@skinbiotix.com
|
Singer Capital Markets (Nominated Adviser & Broker)Philip DaviesJames ToddPatrick Weaver | +44 (0) 020 7496 3000
|
Vigo Consulting Melanie Toyne-SewellRozi Morris | +44 (0) 20 7390 0230 SkinBio@vigoconsulting.com |
|
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.
The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.
The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.
Follow the stocks
